OTCMKTS:IDRSF Idorsia (IDRSF) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free IDRSF Stock Alerts $1.95 -0.15 (-7.14%) (As of 04/30/2024 ET) Add Compare Share Share Today's Range$1.95▼$1.9550-Day Range$1.65▼$2.8052-Week Range$1.40▼$9.55Volume5,600 shsAverage Volume3,557 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Idorsia alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Idorsia Stock (OTCMKTS:IDRSF)Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.Read More IDRSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDRSF Stock News HeadlinesApril 27, 2024 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 26, 2024 | finance.yahoo.comJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionApril 30, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 23, 2024 | globenewswire.comIdorsia publishes an invitation to a bondholder meetingApril 17, 2024 | finance.yahoo.comIdorsia publishes a Financial Status required for an upcoming bondholder meetingApril 11, 2024 | globenewswire.comIdorsia takes steps to address short-term liquidity needsMarch 22, 2024 | bizjournals.comIdorsia gets FDA approval for high blood pressure drug TryvioMarch 22, 2024 | seekingalpha.comIdorsia: Aprocitentan Approval Is A Vital NewsApril 30, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 22, 2024 | globenewswire.comIdorsia thanks Guy Braunstein for his years of service as he retiresMarch 20, 2024 | msn.comFDA approves Idorsia’s once-daily antihypertensive TryvioMarch 20, 2024 | msn.comIdorsia gets FDA approval for hypertension drug TryvioMarch 20, 2024 | finance.yahoo.comIdorsia Ltd (IDRSF) Stock Historical Prices & Data - Yahoo FinanceMarch 20, 2024 | globenewswire.comUS FDA approves Idorsia's once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensivesMarch 8, 2024 | finance.yahoo.comWhat Does The Future Hold For Idorsia Ltd (VTX:IDIA)? These Analysts Have Been Cutting Their EstimatesMarch 7, 2024 | realmoney.thestreet.comKepler Cheuvreux gets more bullish on Idorsia, upgrades sharesFebruary 28, 2024 | markets.businessinsider.comViatris, Idorsia Announce Global Research And Development CollaborationFebruary 6, 2024 | markets.businessinsider.comHere's what to expect from Idorsia's earningsJanuary 10, 2024 | finance.yahoo.comIdorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creationDecember 6, 2023 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insidersOctober 25, 2023 | msn.comIdorsia Q3 Review: Not The Quarter We ExpectedOctober 24, 2023 | msn.comIdorsia GAAP EPS of CHF0.96, revenue of CHF80MOctober 24, 2023 | finance.yahoo.comIdorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable valueOctober 24, 2023 | marketwatch.comIdorsia Shares Fall on Funding NeedsOctober 23, 2023 | finance.yahoo.comIdorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023September 15, 2023 | msn.comNICE recommends Idorsia’s chronic insomnia treatment for UK patientsSeptember 6, 2023 | uk.finance.yahoo.comIdorsia reacquires the world-wide rights to aprocitentanSee More Headlines Receive IDRSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IDRSF CUSIPN/A CIKN/A Webwww.idorsia.com Phone(158) 844-0000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Jean-Paul Clozel M.D. (Age 69)CEO & Executive Director Comp: $1.5MMr. André C. Muller (Age 61)Executive VP & CFO Dr. Martine Clozel (Age 69)Executive VP & Chief Scientific Officer Mr. Andrew C. Weiss (Age 56)Senior VP and Head of Investor Relations & Corporate Communications Mr. Julien Gander L.L.M. (Age 45)Senior VP, Group General Counsel & Company Secretary Mr. Alexander Khatuntsev (Age 46)Senior VP & Head of Global Human Resources Dr. Guy Braunstein M.D. (Age 68)Executive VP & Chief Medical Officer Mr. Olivier Lambert (Age 58)Senior VP & Head of Technical Operations Mr. Markus A. Riederer (Age 62)Senior VP & Head of Drug Discovery Biology Mr. Christoph Boss (Age 56)Senior VP & Head of Drug Discovery Chemistry More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IDRSF Stock Analysis - Frequently Asked Questions Should I buy or sell Idorsia stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last twelve months. There are currently 2 sell ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" IDRSF shares. View IDRSF analyst ratings or view top-rated stocks. How have IDRSF shares performed in 2024? Idorsia's stock was trading at $2.45 at the beginning of 2024. Since then, IDRSF stock has decreased by 20.4% and is now trading at $1.95. View the best growth stocks for 2024 here. Are investors shorting Idorsia? Idorsia saw a decrease in short interest in March. As of March 31st, there was short interest totaling 8,420,100 shares, a decrease of 7.6% from the March 15th total of 9,112,700 shares. Based on an average daily trading volume, of 6,500 shares, the short-interest ratio is currently 1,295.4 days. View Idorsia's Short Interest. How do I buy shares of Idorsia? Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IDRSF) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersThe Gold Grab of the CenturyColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss RatingsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIs Tesla going out of business?DTITrump’s last act as President Porter & CompanyJeff Bezos Just Humiliated Elon MuskInvestorPlaceElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
